{
    "ticker": "CMPS",
    "name": "Compass Pathways plc",
    "description": "Compass Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Founded in 2016, Compass is focused on developing psychedelic therapies for treatment-resistant depression and other mental health conditions. The company is pioneering the use of psilocybin therapy, a compound found in certain mushrooms, in combination with psychological support to create a holistic treatment approach. Compass has established rigorous clinical trials to assess the safety and efficacy of its products, aiming to address the significant unmet need for effective treatments in mental health. The company's lead product candidate, COMP360, is currently undergoing Phase IIb clinical trials, which have shown promising results in reducing symptoms of depression. Through its innovative approach and commitment to scientific research, Compass Pathways is striving to transform the mental health landscape and improve the lives of millions suffering from mental health disorders. The company operates with a mission to develop safe and effective treatments that can be accessible globally, with the ultimate goal of alleviating the burden of mental illness.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2016",
    "website": "https://www.compasspathways.com",
    "ceo": "George Goldsmith",
    "social_media": {
        "twitter": "https://twitter.com/CompassPathways",
        "linkedin": "https://www.linkedin.com/company/compass-pathways/"
    },
    "investor_relations": "https://investors.compasspathways.com",
    "key_executives": [
        {
            "name": "George Goldsmith",
            "position": "CEO"
        },
        {
            "name": "Catherine Jacobson",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Psychedelic Therapies",
            "products": [
                "COMP360"
            ]
        }
    ],
    "seo": {
        "meta_title": "Compass Pathways plc | Transforming Mental Health with Psilocybin Therapy",
        "meta_description": "Explore Compass Pathways, a leader in mental health innovation focused on developing psilocybin therapy for treatment-resistant depression and other mental health conditions.",
        "keywords": [
            "Compass Pathways",
            "Mental Health",
            "Psychedelic Therapy",
            "Psilocybin",
            "Depression Treatment",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Compass Pathways do?",
            "answer": "Compass Pathways is focused on developing psychedelic therapies for mental health conditions, particularly treatment-resistant depression."
        },
        {
            "question": "What is COMP360?",
            "answer": "COMP360 is Compass Pathways' lead product candidate, a psilocybin therapy combined with psychological support."
        },
        {
            "question": "Where is Compass Pathways headquartered?",
            "answer": "Compass Pathways is headquartered in London, United Kingdom."
        },
        {
            "question": "When was Compass Pathways founded?",
            "answer": "Compass Pathways was founded in 2016."
        }
    ],
    "competitors": [
        "ATAI",
        "SNDL",
        "MMEDF"
    ],
    "related_stocks": [
        "NVCR",
        "AXSM",
        "SAGE"
    ]
}